Newsletter | August 17, 2019

08.17.19 -- Bury The Hatch-Waxman: Generics Were Not The Answer

 
From The Editor
Bury The Hatch-Waxman: Generics Were Not The Answer
 
By Louis Garguilo, Chief Editor, Outsourced Pharma

The hypothesis is bold: Our emphasis on generics is a detriment to U.S. patients and the entire healthcare system. Instead, these past decades we should have focused intently on increasing the life cycle and distribution of innovator drugs.

The Next Generation Appreciates Our Outsourcing Industry
By Louis Garguilo, Chief Editor, Outsourced Pharma
Featured Editorial
Equipment Change Control For GMP Production Facilities: Proving It All Works
By Greg Weilersbacher, Eastlake Quality Consulting
4 Trends In Recent FDA Warning Letters To OTC Drugmakers: And How To Avoid Them
By Alan D. Greathouse, The FDA Group, LLC
Solutions
Services And Equipment
Pharmaceutics International
Contract Development And Manufacturing: A CDMO Beyond Measure
Samsung BioLogics
Sterile Injectables Fill-Finish
Pfizer CentreOne Contract Manufacturing
Small Molecule API
Thermo Fisher Scientific
Connect With Outsourced Pharma:
   LinkedIn